Savara Inc.
NASDAQ:SVRA · NASDAQ Global Select
+$0.03 today
Vol 3.57M · Avg 1.53M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $38.8M |
| Short-term Investments | $164.0M |
| Receivables | $1.1M |
| Other Current | $5.4M |
| Total Current Assets | $209.3M |
| PP&E (Net) | $130.0K |
| Intangible Assets | $11.4M |
| Other Non-current | $886.0K |
| Total Non-current Assets | $12.4M |
| Total Assets | $221.6M |
Analysis
Selected assets total $221.6M for Latest. The largest visible component is Short-term Investments at $164.0M, about 74.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $33.2M +119.3% | $15.1M -43.1% | $26.6M -49.0% | $52.1M +53.2% | $34.0M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $202.5M +11.8% | $181.2M +33.5% | $135.7M +84.0% | $73.8M -42.0% | $127.2M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $1.3M +20.2% | $1.0M +3.8% | $1.0M +5.3% | $954.0K -16.6% | $1.1M | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 -100.0% | $2.1M +279.5% | -$1.1M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $1.3M +182.6% | $455.0K +62.5% | $280.0K +114.1% | -$2.0M -232.1% | $1.5M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $241.6M +19.5% | $202.1M +21.8% | $165.9M +28.7% | $129.0M -21.8% | $165.0M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $100.0K -39.4% | $165.0K -38.9% | $270.0K +429.4% | $51.0K -30.1% | $73.0K | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $11.6M +12.6% | $10.3M -5.7% | $11.0M +2.9% | $10.7M -5.5% | $11.3M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $84.0K -65.3% | $242.0K -37.5% | $387.0K +233.6% | $116.0K -53.8% | $251.0K | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $11.8M +10.0% | $10.7M -7.5% | $11.6M +7.3% | $10.8M -6.7% | $11.6M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $253.4M +19.1% | $212.9M +19.9% | $177.6M +27.0% | $139.8M -20.9% | $176.6M | $13.3B | $11.9B | $10.6B |
| Account Payables | $5.8M +26.7% | $4.5M +29.7% | $3.5M +162.7% | $1.3M -7.6% | $1.4M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $7.0K | $0 | $0 | $0 -100.0% | $8.3M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $8.1M +61.1% | $5.0M +24.0% | $4.0M | $0 | $0 | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $20.4M +38.5% | $14.7M +38.9% | $10.6M +80.6% | $5.9M -60.0% | $14.7M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $29.9M +12.4% | $26.6M +1.0% | $26.3M +1.0% | $26.1M +50.5% | $17.3M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 -100.0% | $87.0K -64.8% | $247.0K +357.4% | $54.0K -53.8% | $117.0K | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $29.9M +12.0% | $26.7M +0.4% | $26.6M +1.8% | $26.1M +49.8% | $17.4M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $50.3M +21.4% | $41.4M +11.4% | $37.2M +16.2% | $32.0M -0.3% | $32.1M | $14.7B | $3.7B | $9.6B |
| Common Stock | $204.0K +17.9% | $173.0K +23.6% | $140.0K +20.7% | $116.0K +0.0% | $116.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$608.1M -24.3% | -$489.3M -24.4% | -$393.4M -16.2% | -$338.7M -12.7% | -$300.5M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$87.0K +88.4% | -$750.0K -176.8% | -$271.0K +55.2% | -$605.0K -12200.0% | $5.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $203.1M +18.5% | $171.4M +22.1% | $140.4M +30.2% | $107.8M -25.4% | $144.5M | $9.1B | $7.7B | $3.3B |
| Total Debt | $29.9M +11.9% | $26.7M +0.9% | $26.5M +1.3% | $26.1M +1.4% | $25.8M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$3.3M -128.1% | $11.6M +12447.9% | -$94.0K +99.6% | -$26.0M -215.8% | -$8.2M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.55B
Nanobiotix S.A.
NASDAQ:NBTX
$1.78B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.67B
GH Research PLC
NASDAQ:GHRS
$1.48B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.25B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.12B
Kura Oncology, Inc.
NASDAQ:KURA
$854.90M
Geron Corporation
NASDAQ:GERN
$821.15M
Rezolute, Inc.
NASDAQ:RZLT
$487.72M
ProKidney Corp.
NASDAQ:PROK
$261.50M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does SVRA have?
Savara Inc. (SVRA) reported $33.18M in cash and equivalents in fiscal 2025.
How much debt does SVRA carry?
Savara Inc. (SVRA) reported $29.91M of total debt, with net debt of -$3,266,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.